RPL38

Across TCGA pan-cancer cohorts, RPL38 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL38 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RPL38 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL38 expression acts as an unfavorable survival marker.

GBM, CCRCC, and PDAC are the cancer types where RPL38 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.243	0.530	<.001	24	view →
CCRCC	OS	Tertile	All	0.885	1.000	.013	18	view →
PDAC	OS	Median	All	0.695	0.946	.002	7	view →
LUAD	OS	Tertile	II,III,IV	0.525	1.000	.022	5	view →
LSCC	OS	Tertile	All	0.669	1.000	.012	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL38–GBM (DFS)

Open the GBM breakdown →